LifeVantage Corporation reported its financial results for the second fiscal quarter ended December 31, 2025. The company generated revenue of $48.9 million, reflecting a 2.9% increase compared to the previous quarter, while declining 27.8% year over year. Revenue in the Americas decreased by 32.6%, whereas the Asia/Pacific and Europe regions demonstrated relative stability, posting a modest decline of 2.1%.
The company cited revenue pressures primarily from lower sales of the MindBody GLP-1 System, while noting that the acquisition of LoveBiome and the expansion of the LoveBiome product line partially offset the decline. Gross profit for the period was $36.2 million, accounting for 74% of total revenue, compared with $54.6 million, or 80.5% of revenue, in the same period of the prior year.
Adjusted EBITDA for the period totaled $3.9 million, declining from $6.5 million in the corresponding period of the prior year. Operating income was $0.5 million, compared with $3.4 million reported in the same period last year.
Steve Fife, President and Chief Executive Officer of LifeVantage, stated that the second quarter was impacted by heightened competitive pressures in the weight loss market, coinciding with the anniversary of the MindBody GLP-1 System launch in October 2024. He acknowledged that the company’s performance fell short of both management and stakeholder expectations and emphasized that LifeVantage is intensifying efforts to stabilize the GLP-1 business while implementing broader strategic initiatives to restore revenue growth. Despite a shift in the growth trajectory of MindBody, the company remains confident in the product’s scientifically validated, natural weight loss solution. Fife highlighted LifeVantage’s strong positioning within the broader health and wellness ecosystem and expressed optimism around the accelerating momentum of LoveBiome, supported by several new product launches planned over the coming quarters that will expand into adjacent, high-growth categories. Additionally, the company intends to enter new international markets beginning this summer, reinforcing its long-term growth strategy. With a solid balance sheet and a demonstrated history of returning capital to shareholders, LifeVantage remains focused on delivering sustainable, long-term shareholder value.
Get more information
There are no reviews yet. Be the first one to write one.
